At Medicilon, we’re proud to be at the forefront of this transformation. Our NAMs Drug R&D Service Platform integrates AI-driven modelling, advanced in vitro systems, and dry-wet integration to accelerate discovery, improve prediction accuracy, and meet evolving regulatory expectations.
What makes our NAMs platform unique:
AI-assisted drug discovery: From target identification to hit-to-lead and lead optimisation.
In vitro safety assessment: Cardio-, hepato, and nephrotoxicity, cytokine release, immunotoxicity, and more.
PDXO biobank and organoid models: Human-relevant systems for efficacy and safety evaluation.
PBPK modelling: Predicting human pharmacokinetics from preclinical data.
With NAMs, we’re reducing reliance on animal studies while increasing human relevance, efficiency, and sustainability in drug R&D.
Let’s connect or reach out directly:
Email: [email protected] Tel: +44 1223981791
Global Headquarters: 585 Chuanda Road, Pudong, Shanghai, 201299, China
UK Office: Ailla Future Business Centre, King's Hedges Road, Cambridge, CB4 2HY